Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Illumina faces short-read rivals

Nature Biotechnology volume 41, pages 3–5 (2023)Cite this article

New sequencers are poised to disrupt Illumina’s dominance. Users will need to navigate the opportunities and challenges on offer in an increasingly crowded market.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Philadelphia, PA, USA

    Michael Eisenstein

Authors
  1. Michael Eisenstein
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eisenstein, M. Illumina faces short-read rivals. Nat Biotechnol 41, 3–5 (2023). https://doi.org/10.1038/s41587-022-01632-4

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-022-01632-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing